Mivocabtagene Autoleucel CD19 CAR T-Cell Therapy in Stiff Person Syndrome: Efficacy, Safety, and Emerging Clinical Paradigm

Highlights

  • Mivocabtagene autoleucel demonstrated significant and sustained improvement in motor function in antibody-positive stiff person syndrome (SPS) patients refractory to standard immunotherapies.
  • Safety profile included manageable neutropenia and mostly low-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) that resolved without sequelae.
  • Observed B-cell depletion and immune reset indicate mechanistic engagement of pathogenic B-cell populations driving SPS autoimmunity.
  • This study introduces a novel immunotherapy paradigm with durable, immunomodulation-free remission potential in SPS, a disease previously lacking highly effective interventions.

Background

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply